Skip to content
Lupus Association of NSW Inc.
Lupus Association of NSW Inc.
The Quest for a Cure
1800 802 088

Donate Now

  • Home
  • Understanding Lupus
    • What is Lupus?
    • Signs and Symptoms of Lupus
    • Diagnosing Lupus
    • FAQs about Lupus
  • How lupus affects the body
    • How does lupus affect the body
    • Lupus and the Kidneys
    • Infections
    • Photosensitivity
  • Living with Lupus
    • Lupus and COVID-19
    • Coronavirus, stress and mental health
    • Looking after your well-being
    • Tips for Living with Lupus
    • Diet and Exercise
    • Medications
    • Managing Pain
    • Managing Fatigue
  • Sjogren’s Syndrome
    • What is Sjögren’s Syndrome?
    • Signs and Symptoms of Sjögren’s
    • Diagnosing Sjögren’s Syndrome
    • Treating Sjögren’s Syndrome
    • Tips for Living with Sjögren’s Syndrome
  • News
    • News and Events
    • Lupus Stories
    • Research
      • Research and Reports
      • The Monash Lupus Clinic
  • About Us
    • Mission Statement
    • Our History
    • Contact
    • Privacy Policy
    • Support
    • Other Lupus Websites
    • Donate
  • Home
  • Understanding Lupus
    • What is Lupus?
    • Signs and Symptoms of Lupus
    • Diagnosing Lupus
    • FAQs about Lupus
  • How lupus affects the body
    • How does lupus affect the body
    • Lupus and the Kidneys
    • Infections
    • Photosensitivity
  • Living with Lupus
    • Lupus and COVID-19
    • Coronavirus, stress and mental health
    • Looking after your well-being
    • Tips for Living with Lupus
    • Diet and Exercise
    • Medications
    • Managing Pain
    • Managing Fatigue
  • Sjogren’s Syndrome
    • What is Sjögren’s Syndrome?
    • Signs and Symptoms of Sjögren’s
    • Diagnosing Sjögren’s Syndrome
    • Treating Sjögren’s Syndrome
    • Tips for Living with Sjögren’s Syndrome
  • News
    • News and Events
    • Lupus Stories
    • Research
      • Research and Reports
      • The Monash Lupus Clinic
  • About Us
    • Mission Statement
    • Our History
    • Contact
    • Privacy Policy
    • Support
    • Other Lupus Websites
    • Donate

US FDA approve Benlysta

GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease.

Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was first approved for systemic lupus erythematosus in 2011.

One of the most common and serious complications of systemic lupus erythematosus, lupus nephritis is inflammation in the kidneys. Too often, this damage necessitates regular dialysis or a transplanted organ to do the work of the kidneys in filtering wastes from the body.

“The FDA’s approval of Benlysta for lupus nephritis represents an important milestone in treating one of the most serious consequences of lupus,” said Stevan W. Gibson, president and CEO, Lupus Foundation of America. “Between 10 and 30 percent percent of people with lupus nephritis will develop end-stage renal disease or kidney failure. Effective treatment can greatly improve health outcomes and reduce the long-term costs associated with managing lupus-related kidney disease.”

The recent approval by the FDA follows on from the Pharmaceutical Benefits Advisory Committee (PBAC) decision in October 2020 to reject Benlysta being included on the Pharmaceutical Benefits Scheme. This is the second submission to the PBAC that has been rejected despite attempts put forward to mitigate the uncertainties identified.

Lupus Australia remains disappointed by the PBAC’s decision not to recommend Benlysta® (belimumab) administered subcutaneously for the treatment of patients with systemic lupus erythematosus (SLE), given this is the only new therapy to be approved by the Therapeutic Goods Administration for this indication in 50 years.

Author: admin

Post navigation

PreviousPrevious post:US FDA approves Lupkynis (voclosporin)NextNext post:Phase 3 Trial – Benlysta

Related posts

Lupus Clinical Trial Awareness in Australia – Now Closed
12/03/2023
Lupus Sub Group of Type 2
10/08/2022
mRNA COVID-19 Vaccine
01/08/2022
WLF Global Survey of People Living with Lupus
05/05/2022
New cutaneous lupus erythematosus clinical trial in Victoria
13/09/2021
FDA Approves Saphnelo™ as New Treatment for Lupus
06/08/2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

clear formPost comment

Stay in touch
Address: 55 Wicks Rd
North Ryde NSW 2113
 
Phone: (02) 9878 6055
Email: info@lupusaust.org.au
A.B.N: 25 876 911 996
Useful Links
  • Other Lupus Websites
Latest Tweets
World Lupus Day is Wednesday May 10. Let's work together to raise awareness and beat this monster!
Donations
  • How To Donate
  • Privacy Policy
Donate Now!
© Lupus Association of NSW Inc.

Webmaster - admin@lupusnsw.org.au